Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Figure 2 Overall and progression-free survival with different stratifications. A: The overall survival (OS) and progression-free survival (PFS) in Barcelona Clinic Liver Cancer stage (C vs B) patients; B: The OS and PFS in early neutrophil lymphocyte ratio response (decrease vs increase) patients; C: The OS and PFS in early alpha fetoprotein response (decrease ≤ 20% vs > 20%) patients. AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer Classification; OS: Overall survival; PFS: Progression-free survival; NLR: Neutrophil lymphocyte ratio.